IPP Bureau
Eugia Pharma receives USFDA approval for Vasopressin Injection USP
By IPP Bureau - August 16, 2022
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
Unichem receives ANDA approval for quetiapine extended-release tablets
By IPP Bureau - August 16, 2022
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD)
BeiGene announces strategic alliance with Ontada to improve US community oncology care
By IPP Bureau - August 16, 2022
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital
By IPP Bureau - August 16, 2022
Company appoints five new independent directors to reconstituted board
Fish & Richardson secures win for Exela Pharma Sciences in ELCYS patent infringement litigation
By IPP Bureau - August 16, 2022
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
QIAGEN launches syndromic test for QIAstat-Dx device to combat Monkeypox health emergency
By IPP Bureau - August 16, 2022
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Yashoda Hospitals successfully performs bariatric surgery
By IPP Bureau - August 15, 2022
Man lost 54 Kgs in 6 months with MGB procedure
ENHERTU delays disease progression in DESTINYBreast02 Phase 3 Trial
By IPP Bureau - August 15, 2022
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Arbitrator rules in favor of Daiichi Sankyo in dispute with Seagen
By IPP Bureau - August 15, 2022
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
SPARSH Hospital organises a walkathon to create awareness on organ donation
By IPP Bureau - August 15, 2022
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
Parmax Pharma posts Q1 FY 23 loss at Rs. 1.31 Cr
By IPP Bureau - August 14, 2022
The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022
Nectar Lifesciences posts Q1 FY23 consolidated PAT at Rs. 3.89 Cr
By IPP Bureau - August 14, 2022
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr
By IPP Bureau - August 14, 2022
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
Lupin receives USFDA approval for Meclizine Hydrochloride Tablets USP
By IPP Bureau - August 13, 2022
The product will be manufactured at Lupin’s facility in Goa, India.
Vascular experts establish appropriate use of IVUS in peripheral interventions
By IPP Bureau - August 13, 2022
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
